Invadopodia Sample Clauses

Invadopodia. A special protrusion in mediating metastasis 26
AutoNDA by SimpleDocs
Invadopodia. A special protrusion in mediating metastasis Extracellular matrix degradation and invasion is a crucial part of the metastatic cascade (Xxxxxxxxx and Xxxxxxxx, 2011). Xxxxx is a well characterised transcriptional factor promoting metastasis. Twist has been shown to upregulate expression of platelet derived growth factor receptor α (PDGFRα) which in turn stimulates Src activity ultimately resulting in the formation of actin rich membrane protrusions which can target the secretion of MMPs and degrade the extracellular matrix in human mammary epithelial HMLE cells(Xxxxxx et al., 2011), (figure 1.3). These structures are known as invadopodia and have been implicated in the local invasion, intravasation and metastasis of breast cancer cells to the lung (Xxxxxx et al., 2011; Xxxxxxxxxxxx et al., 2012). In fact, recent advances in intravital microscopy have also allowed the visualisation of extravasating MDA-MB-231LN cells extending invadopodia into the extravascular stroma of the chorioallantoic membrane (CAM) of the chicken embryo (Xxxxx et al., 2014). Invadopodia are complex structures incorporating adhesion proteins, actin binding proteins, metalloproteases with Rho GTPases and their effectors contributing to their dynamic formation and activity (Xxxxxx and Xxxxxxxxxxx, 2011). Extracellular signals stimulate the formation of invadopodia via the activation of plasma membrane receptors initiating signalling cascades (Xxxxxxx et al., 2013). In breast cancer cells activation of EGFR, Met and TGFβ receptors has been shown to induce formation of invadopodia (Xxxxxx et al., 2008; Xxxxxxxxx et al., 2012; Xxxxxxxxx et al., 2005). Similar results have been reported for head and neck squamous carcinoma cells when VEGF becomes activated (Xxxxx et al., 2010). Activation of these signalling cascades meet at stimulating a set of kinases, particularly Src but also ERK and PAKs that induce the formation of invadopodia (Xxxxxx et al., 2016). Src phosphorylates various substrates including cortactin and Tks5 which constitute hallmark elements of invadopodia formation (Xxxxxx and Courtneidge, 2011), (figure 1.3). Tks5 is an adaptor protein shown to be crucial for invadopodia formation by specifically localising early and marking invadopodia sites as well as acting as a scaffold for other invadopodia elements such as cortactin (Xxxxxxxx et al., 2009; Xxxxxx and Xxxxxxxxxxx, 2011; Xxxxx et al., 2005). PAK1 mediated phosphorylation of cortactin Ser113 has been shown to be important...
Invadopodia. Formation of invadopodia is considered indicative of invasive potential in vitro and in vivo (Xxxxxx et al., 2011; Xxxxx et al., 2014). We sought to examine the invasive potential of our cell lines knowing that MB-231 cells are widely used in invadopodia research (Xxxxx et al., 2011) . In order to detect invadopodia formation in vitro, cells were seeded on glass coverslips previously coated with TRITC-conjugated gelatin. To allow invadopodia formation to occur cells were incubated at 37°C for 3h and were subsequently fixed with PFA and stained with Phalloidin 488 resulting in green stained cells over a red stained matrix (Hashim et al., 2013). Cells were considered able to make invadopodia when the actin puncta revealed by the phalloidin stain indicating the protrusive structure of invadopodia coincided with black holes in the red gelatin indicating matrix degradation (Xxxxxx et al., 2013). Out of the 4 cell lines that were subjected to the assay the HCC38 and MB-436 cells did not make any invadopodia (figure 3.7). Interestingly, reviewing the literature revealed that there is no published evidence of HCC38 or MB-436 cells being used in invadopodia assays. Together, these observations suggest that the HCC38 and MB-436 cells do not make invadopodia. As expected, the MB-231 cells exhibited definitive evidence of invadopodia formation and activity (figure 3.7A, 3.7B) which is consistent with their widespread use in invadopodia research. The BT-549 cells showed very little evidence of invadopodia presence at the 3h incubation as only a few very small invadopodia were detected. This observation suggested that the BT-549 cells might require longer incubations on the gelatin matrix to form active invadopodia. Further characterisation of the invadopodia capacity of the BT-549 cells was thus warranted. A Invadopodia formation at 3 hours 30 % of cells making invadopodia B 20 10 0 MB-231 BT-549 HCC38 MB-436 Cell lines Figure 3.7 Invadopodia assay at 3h. (A) Cells were seeded on TRITC conjugated gelatin coated coverslips and incubated for 3h at 37°C. Coverslips were then fixed and stained with Phalloidin 488 (green) and cells were imaged. Scale bar corresponds to 10μm (B) Percentage of cells making invadopodia was determined for each individual experiment (N=3). Bars represent the mean percentage of cells making invadopodia and error bars represent the SEM.

Related to Invadopodia

  • Kesimpulan Indonesia-Japan Economic Partnership Agreement (IJEPA) merupakan bentuk kerjasama ekonomi bilateral antara Indonesia xxx Jepang yang bertujuan untuk meningkatkan kegiatan impor, ekspor xxx investasi di kedua negara. Kerangka perjanjian ini meliputi liberalisasi perdagangan, investasi, perlindungan hak kekayaan intelektual, transparansi, anti-persaingan, memperdalam kerja xxxx, xxx menetapkan prosedur untuk menegakkan perjanjian. Perjanjian ini terjalin dilandasi oleh kepentingan nasional masing-masing negara. Adapun kepentingan nasional Indonesia dalam perjanjian ini xxxxxx xxxx mengoptimalkan kerjasama antara Indonesia-Jepang, mendapat kepastian akses pasar di Jepang yang lebih luas berkat penurunan tarif, meningkatkan arus barang xxx xxxx, mendapatkan transfer teknologi, sebagai sektor penggerak, program kesejahteraan, xxx juga menjadi pusat pengembangan manufaktur. General Review semestinya diadakan lima tahun setelah dilaksanakannya perjanjian. namun Jepang menunda pelaksanaan kegiatan ini sampai diubahnya Peraturan Menteri Keuangan yang diklaim tidak sesuai dengan IJEPA. Padahal sebelumnya Indonesia sudah menawarkan Jepang agar memberi usulan terkait peraturan ini sebelum diterbitkan. Indonesia masih mengejar kepentingannya untuk memenuhi perundingan ulang terkait tarif bea masuk xxx tarif impor yang belum terlaksana secara efektif. Selain berkenaan tentang kepentingan nasional, Indonesia sebenarnya juga tidak menetapkan tujuan yang jelas yang akan dicapai dalam kerjasama ekonomi ini. Diplomasi ekonomi yang diupayakan indonesia dalam kerjasama ekonomi bilateral ini didasari oleh beberapa faktor seperti latar belakang sejarah, hubungan perdagangan xxxx xxxxxx menguntungkan, xxx juga kemajuan perekonomian Jepang. Indonesia juga bergantung kepada situasi ekonomi Jepang karena kegiatan impor,ekspor, xxx investasi yang berlangsung memberi dampak terhadap pertumbuhan ekonomi Indonesia dilihat dari nilai perdagangan yang terus mengalami tren kenaikan. Meskipun menguntungkan,Indonesia harus terus bersikap tegas dalam melaksanakan perjanjian ini xxxxxx xxxxx banyak kepentingan nasional dari kerjasama bilateral ini yang belum sepenuhnya tercapai. Melalui analisis komprehensif terhadap kendala yang tidak kondusif bagi Indonesia dalam tinjauan umum IJEPA. Indonesia akan melanjutkan upayanya untuk mewujudkan kepentingan nasionalnya melalui kerja sama ini. Kerja sama ini diharapkan dapat terus meningkatkan hubungan baik perekonomian antara Indonesia-Jepang. DAFTAR PUSTAKA Anggraeni, N. A. (2020). DIPLOMASI EKONOMI JEPANG DALAM UPAYA PERPINDAHAN LIMBAH B3 MELALUI INDONESIA-JAPAN ECONOMIC PARTNERSHIP AGREEMENT (IJEPA). Jurnal PIR: Power in International Relations, 3(2), 156-172. Ardiyanti, S. T. (2015). Dampak Perjanjian Perdagangan Indonesia - Jepang (Ijepa) Terhadap Kinerja Perdagangan Bilateral. Buletin Ilmiah Litbang Perdagangan, 9(2), 129–151. xxxxx://xxx.xxx/10.30908/bilp.v9i2. 5 Arifin Rivai, A. N. (2017). Posisi Indonesia di Tengah Fenomena Korporasi Global (Studi Kasus: Relasi Dagang Indonesia – Toyota Pasca Kesepakatan IJEPA). Indonesian Perspective, 2(2), 105. xxxxx://xxx.xxx/10.14710/ip.v2i2.18 474 Xxxxxxxxx Xxxxxx. (2019). Faktor Penghambat Peningkatan Investasi Jepang di Indonesia dalam Kerangka Kerja IJEPA 208-2018. Universitas Katolik Parahyangan. Gocklas C.S, L., & Sulasmiyati, S. (2017). Analisis Pengaruh Indonesia-Japan Economic Partnership Agreement (IJEPA) Terhadap Nilai Perdagangan Indonesia-Jepang (Studi Pada Badan Pusat Statistik 2000-2016). Jurnal Administrasi Bisnis (JAB)|Vol, 50(5), 191–200. xxxxx://xxxxx.xxxxxx.xxx/media/pub lications/188892-ID-analisis- pengaruh-indonesia-japan- econom.pdf Hadi, S. (2014). Indonesia-Japan Economic Partnership Agreement: an Indonesian Perspective. East Asian Policy, 06(03), 114–128. xxxxx://xxx.xxx/10.1142/s17939305 14000312 Harahap, I. K., & Xxxxxx, A. M. (2015). DAMPAK PENERAPAN INDONESIA-JAPAN ECONOMIC PARTNERSHIP AGREEMENT TERHADAP EKSPOR INDONESIA KE JEPANG. Media Ekonomi, 23(1), 27. xxxxx://xxx.xxx/10.25105/me.v23i1. 0000 Xxxxxx, X. S. (2016). KEGAGALAN INDONESIA DALAM IMPLEMENTASI INDONESIAN JAPAN ECONOMIC PARTNERSHIP AGREEMENT (IJEPA). Jurnal Lyceum, 4(1), 430–439. Kementerian Perdagangan Republik Indonesia. (2015). Analisis Review Indonesia Japan Economic Partnership Agreement (IJEPA) dalam Perdagangan Barang. xxxxx://xxx.xxx/10.1108/eb057810

  • xxx/OpenGovernment/LobbingAtOrangeCounty aspx A lobbying blackout period shall commence upon issuance of the solicitation until the Board selects the Contractor. For procurements that do not require Board approval, the blackout period commences upon solicitation issuance and concludes upon contract award. The County may void any contract where the County Mayor, one or more County Commissioners, or a County staff person has been lobbied in violation of the black-out period restrictions of Ordinance No. 2002-15. • Orange County Protest Procedures xxxx://xxx.xxxxxxxxxxxxxx.xxx/VendorServices/XxxxxxXxxxxxxXxxxxxxxxx.xx px Failure to file a protest with the Manager, Procurement Division by 5:00 PM on the fifth full business day after posting, shall constitute a waiver of bid protest proceedings.

  • Exportbepalingen Het is u niet toegestaan de Apple software te gebruiken of anderszins te exporteren of te herexporteren, behalve voor zover toegestaan krachtens de wetten van de Verenigde Staten en van het rechtsgebied waarin u de Apple software hebt verkregen. In het bijzonder, maar zonder beperking, is het u niet toegestaan de Apple software te exporteren of te herexporteren (a) naar een land waarvoor door de Verenigde Staten een embargo is ingesteld of (b) naar enige persoon die voorkomt op de door het U.S. Treasury Department samengestelde lijst van "Specially Designated Nationals" of op de door het U.S. Department of Commerce samengestelde "Denied Person’s List" of "Entity List". Door de Apple software te gebruiken, verklaart u dat u zich niet bevindt in een dergelijk land of op een van de bovengenoemde lijsten voorkomt. U verklaart tevens dat u de Apple software niet zult gebruiken voor doeleinden die verboden zijn volgens de wetten van de Verenigde Staten met inbegrip van, maar niet beperkt tot, de ontwikkeling, het ontwerp, de fabricage of productie van raketten, nucleaire, chemische of biologische wapens.

  • Gouvernement des États-Unis Le logiciel et la documentation constituent des « Commercial Items » (éléments commerciaux), tel que ce terme est défini dans la clause 48 C.F.R. (Code of Federal Rules) §2.101, consistant en « Commercial Computer Software » (logiciel) et « Commercial Computer Software Documentation » (documentation), tels que ces termes sont utilisés dans les clauses 48 C.F.R. §12.212 ou 48 C.F.R. §227.7202. Conformément à la clause 48 C.F.R. §12.212 ou 48 C.F.R. §227.7202-1 à 227.7202-4, le « Commercial Computer Software » et le « Commercial Computer Software Documentation » sont fournis sous licence au gouvernement des États-Unis (a) uniquement comme « Commercial Items » et (b) uniquement accompagnés des droits octroyés à tous les autres utilisateurs conformément aux termes et conditions ci-inclus. Droits non publiés réservés en vertu de la législation des droits d’auteur en vigueur aux États-Unis.

  • Prosthodontics We Cover prosthodontic services as follows: • Removable complete or partial dentures, for Members 15 years of age and above, including six (6) months follow-up care; • Additional services including insertion of identification slips, repairs, relines and rebases and treatment of cleft palate; and • Interim prosthesis for Members five (5) to 15 years of age. We do not Cover implants or implant related services. Fixed bridges are not Covered unless they are required: • For replacement of a single upper anterior (central/lateral incisor or cuspid) in a patient with an otherwise full complement of natural, functional and/or restored teeth; • For cleft palate stabilization; or • Due to the presence of any neurologic or physiologic condition that would preclude the placement of a removable prosthesis, as demonstrated by medical documentation.

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

  • meminta nasihat daripada Pihak Xxxxxx dalam semua perkara berkenaan dengan jualan lelongan, termasuk Syarat-syarat Jualan (iii) membuat carian Hakmilik Xxxxx xxxxxx rasmi di Pejabat Tanah xxx/atau xxxx-xxxx Pihak-pihak Berkuasa yang berkenaan xxx (iv) membuat pertanyaan dengan Pihak Berkuasa yang berkenaan samada jualan ini terbuka kepada semua bangsa atau kaum Bumiputra Warganegara Malaysia sahaja atau melayu sahaja xxx juga mengenai persetujuan untuk jualan ini sebelum jualan lelong.Penawar yang berjaya (“Pembeli”) dikehendaki dengan segera memohon xxx mendapatkan kebenaran pindahmilik (jika ada) daripada Pihak Pemaju xxx/atau Pihak Tuanpunya xxx/atau Pihak Berkuasa Negeri atau badan-badan berkenaan (v) memeriksa xxx memastikan samada jualan ini dikenakan cukai. BUTIR-BUTIR HARTANAH : HAKMILIK : Hakmilik strata bagi hartanah ini masih belum dikeluarkan oleh pihak berkuasa. NO. HAKMILIK INDUK / NO. LOT : Geran 203771, Lot 106 Seksyen 3 PEKAN/DAERAH/NEGERI : Pekan Batu Tiga / Petaling / Selangor Darul Ehsan PEGANGAN : Selama-lamanya KELUASAN LANTAI : 93.65 meter persegi (1,008 kaki persegi) PEMAJU : Shanghai Realty (M) Sdn Bhd (350799-U) XXXXXXXX XXX : Xxxxxxxx Xxxxx Bin Xxxxxx BEBANAN : Diserahhak kepada RHB Islamic Bank Berhad (200501003283/680329-V) LOKASI XXX PERIHAL HARTANAH Hartanah tersebut terletak di Pangsapuri Indahria, Xx. 0, Xxxxx Xxxx Xxxx-Xxxxxx Xxxxx, Xxxxx Xxxxxxx, Xxxxxxx 00, 00000 Xxxx Xxxx, Xxxxxxxx Xxxxx Xxxxx. Hartanah tersebut adalah sebuah unit pangsapuri dikenali sebagai Xxxxx Pemaju No. P5-2-11, Tingkat No. 2, Bangunan No. P5, berserta dengan Xxxxx Aksesori No. GRD-07, Pangsapuri Indahria xxx mempunyai alamat surat-menyurat di Unit No. P5-02-11, Pangsapuri Indahria, Xx. 0, Xxxxx Xxxx Xxxx-Xxxxxx Xxxxx, Xxxxx Xxxxxxx, Xxxxxxx 00, 00000 Xxxx Xxxx, Xxxxxxxx Xxxxx Xxxxx. HARGA RIZAB: Harta ini dijual “keadaan seperti mana sediada” dengan harga rizab sebanyak RM 270,000.00 (RINGGIT MALAYSIA: DUA RATUS XXX TUJUH PULUH RIBU SAHAJA) xxx tertakluk kepada syarat-syarat Jualan xxx melalui penyerahan hakkan dari Pemegang Serahak, tertakluk kepada kelulusan di perolehi oleh pihak Pembeli daripada pihak berkuasa, jika ada, termasuk semua terma, syarat xxx perjanjian yang dikenakan xxx mungkin dikenakan oleh Pihak Berkuasa yang berkenaan. Pembeli bertanggungjawab sepenuhnya untuk memperolehi xxx mematuhi syarat- syarat berkenaan daripada Pihak Berkuasa yang berkenaan, jika ada xxx semua xxx xxx perbelanjaan ditanggung xxx dibayar oleh Xxxxx Xxxxxxx.Pembeli atas talian (online) juga tertakluk kepada terma-terma xxx syarat-syarat terkandung dalam xxx.xxxxxxxxxxxxxxxx.xxx Pembeli yang berminat adalah dikehendaki mendeposit kepada Pelelong 10% daripada harga rizab dalam bentuk Bank Draf atau Cashier’s Order di atas nama RHB Islamic Bank Berhad sebelum lelongan awam xxx xxxx xxxx xxxxxx bersama-sama dengan segala cukai jualan xxx perkhidmatan (SST) xxx/atau cukai yang menggantikan SST hendaklah dibayar dalam tempoh sembilan puluh (90) hari dari tarikh lelongan kepada RHB Islamic Bank Berhad melalui XXXXXX. Butir-butir pembayaran melalui XXXXXX, xxxx berhubung dengan Tetuan T. Rajagopalu & Co. Untuk maklumat lanjut, xxxx berhubung dengan TETUAN T. RAJAGOPALU & CO, Solicitors for Assignee herein whose address is at Xxxxx 0-0, Xxxxxxxx Xxxx Xxxxxx Xxxxx Xxxxx, 00000 Xxxxxxxx Xxxxxx Xxxxxxxx. Tel: 00-0000000 / Fax: 00-0000000 [Ruj: RG/RHB/0339/2023/SYAFIQAH(yusof)], peguamcara bagi pihak pemegang xxxxx xxx atau pelelong yang tersebut dibawah. RAJAN AUCTIONEERS SDN. BHD. X. XXXXX Xx.00X,Xxxxxxx Xxxx,Xxxxx Xxxx Xxxxxx, ( Xxxxxxxx Berlesen ) 41000 Klang, Selangor Darul Ehsan. H/P: 000-0000000 Tel: 00-00000000 / Fax : 00-00000000 H/P: 012-2738109 Ruj Kami: RA/RHBI/TRC/NS/4220-24(fz) CONDITIONS OF SALE

  • AT&T-21STATE made an offer (the “Offer”) to all Telecommunications carriers to exchange Section 251(b)(5) Traffic, Non-toll VoIP-PSTN Traffic and ISP-Bound Traffic pursuant to the terms and conditions of the FCC’s interim ISP terminating compensation plan of the FCC’s Order on Remand and Report and Order, In the Matter of Implementation of the Local Competition Provisions in the Telecommunications Act of 1996, Intercarrier Compensation for ISP-Bound Traffic, FCC 01-131, CC Docket Nos. 96-98, 99-68 (rel. April 27, 2001)) (“FCC ISP Compensation Order”) which was remanded but not vacated in WorldCom, Inc. v. FCC, No. 01-1218 (D.C. Cir. 2002).

  • ETHICS IN PUBLIC CONTRACTING This Contract incorporates by reference Article 9 of the Arlington County Purchasing Resolution, as well as all state and federal laws related to ethics, conflicts of interest or bribery, including the State and Local Government Conflict of Interests Act (Code of Virginia § 2.2-3100 et seq.), the Virginia Governmental Frauds Act (Code of Virginia § 18.2-498.1 et seq.) and Articles 2 and 3 of Chapter 10 of Title 18.2 of the Code of Virginia, as amended (§ 18.2-438 et seq.). The Contractor certifies that its proposal was made without collusion or fraud; that it has not offered or received any kickbacks or inducements from any other offeror, supplier, manufacturer or subcontractor; and that it has not conferred on any public employee having official responsibility for this procurement any payment, loan, subscription, advance, deposit of money, services or anything of more than nominal value, present or promised, unless consideration of substantially equal or greater value was exchanged.

  • MEDICAL DEVICES This Article applies when the Goods and/or Services involve UC purchasing or leasing one or more medical devices from Supplier, or when Supplier uses one or more medical devices in providing Goods and/or Services to UC. Medical Device as used herein will have the meaning provided by the U.S. Food and Drug Administration (“FDA”) and means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory which is: (i) recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them; (ii) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or (iii) intended to affect the structure or any function of the body of man or other animals, and which does not achieve any of its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes. Supplier warrants that prior to UC’s purchase or lease of any Medical Device or Supplier’s use of any Medical Device in providing Goods and/or Services hereunder, Supplier will: (i) perform security testing and validation for each such Goods and/or Services or Medical Device, as applicable; (ii) perform a security scan by an anti-virus scanner, with up-to-date signatures, on any software embedded within any Goods and/or Services or Medical Device, as applicable, in order to verify that the software does not contain any known viruses or malware; (iii) conduct a vulnerability scan encompassing all ports and fuzz testing; and (iv) provide UC with reports for (i) – (iii). Supplier warrants that all security testing performed by Supplier covers all issues noted in the “SANS WE TOP 25” and/or “OWASP Top 10” documentation. Throughout Supplier’s performance of this Agreement, Supplier will provide UC with reasonably up-to-date patches, firmware and security updates for any Medical Device provided to UC, and any other Medical Device used in the course of providing Services, as applicable. All such patches and other security updates will be made available to UC within thirty (30) days of its commercial release or as otherwise recommended by Supplier or Supplier’s sub-supplier, whichever is earlier. Supplier warrants that all software and installation media not specifically required for any Medical Device used by Supplier or Goods and/or Services delivered to UC under this Agreement as well as files, scripts, messaging services and data will be removed from all such Goods and/or Services or Medical Device following installation, and that all hardware ports and drives not required for use or operation of such Goods and/or Services or Medical Device will be disabled at time of installation. In addition, Medical Devices must be configured so that only Supplier-approved applications will run on such Medical Devices. Supplier agrees that UC may take any and all actions that it, in its sole discretion, deems necessary to address, mitigate and/or rectify any real or potential security threat, and that no such action, to the extent such action does not compromise device certification, will impact, limit, reduce or negate Supplier’s warranties or any of Supplier’s other obligations hereunder. Supplier warrants that any Medical Device provided to UC, and any other Medical Device used in the course of providing such Goods and/or Services, meet and comply with all cyber-security guidance and similar standards promulgated by the FDA and any other applicable regulatory body. If the Goods and/or Services entail provision or use of a Medical Device, Supplier will provide UC with a completed Manufacturer Disclosure Statement for Medical Device Security (MDS2) form for each such Medical Device before UC is obligated to purchase or lease such Medical Device or prior to Supplier’s use of such device in its performance of Services. If Supplier provides an MDS2 form to UC concurrently with its provision of Goods and/or Services, UC will have a reasonable period of time to review such MDS2 form, and if the MDS2 form is unacceptable to UC, then UC in its sole discretion may return the Goods or terminate the Agreement with no further obligation to Supplier.

Time is Money Join Law Insider Premium to draft better contracts faster.